Detalles del proyecto
| Estado | Finalizado |
|---|---|
| Fecha de inicio/Fecha fin | 7/29/04 → 2/29/12 |
Financiación
- GlaxoSmithKline: 60.029,00 US$
A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) Plus Ritonavir (100mg BID) Versus Lopinavir/Ritonavir (400mg/100mg BID) When Administered in Combination with ...
- Greenberg, Richard (PI)